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The Journal of Thoracic and Cardiovaefore it is over, 2006 will be an interesting, and perhaps exciting, year in
cardiothoracic surgery. On the one hand, after years of clinical and financial
commitment to improving quality of care through scientific analysis of the
ractices undertaken in adult cardiac surgery, we as a specialty are poised to benefit
f our clinical metrics for quality and performance evaluation are adopted. Alterna-
ively, to meet the mandate of “applicability across all providers,” we may be
elegated to a few data metrics collected through administrative data mechanisms,
ffectively rendering these scientific efforts to the sidelines.E1
Both of these scenarios relate to the pay-for-performance (P4P) movement in
edicine, which hits the ground running in 2006.E2 The issue at hand is not whet
4P in some form is going to happen, but rather whether the “scientific investment”
f the past 15 years by cardiothoracic surgeons worldwide, and the results obtained,
arrant consideration beyond “kudos” in this ongoing dynamic.
This “scientific investment” has been nothing short of remarkable, beginning
ith the efforts of the Northern New England Cardiovascular Study Group, the
ormation of the Veterans Administration and Society of Thoracic Surgeons Na-
ional Databases, and the development of the Parsonnet risk-evaluation system. In
urope, similar national database efforts took place, and the EuroSCORE risk-
valuation system was developed and used widely across the continent. I
nited States, voluntary provider-led regional efforts at quality evaluation com-
enced in the face of public reporting of regional outcomes of data from the New
ork State Registry. Numerous large local data systems have been developed and
eported on as well. During the past 7 years the Society for Thoracic Surgeons
ational Cardiac Database has developed into the national platform for quality
valuation and improvement by scientific testing of continuous quality improvement
nd validation of this platform at a national level. These large, mostly observational
fforts have characterized the everyday practice of adult cardiac surgery far more
ccurately than any randomized clinical trial, while benchmarking the incorporation
f important and accurate clinical trial data into everyday clinical practice.
In 2004, stakeholders in the United States reviewed data from this “scientific
nvestment” and documented remarkable declines in risk-adjusted mortality and
orbidity in all adult cardiac surgery procedures, as well as adoption of processes
ocumented to improve quality of care by current evidence-based medicine. This in
art resulted in the 21 metrics selected and approved in 2005 by the 4 Councils and
oard of the National Quality Forum for the evaluation of performance and quality
f cardiac surgical programs in the United States. This metric set illustrates that a
rerequisite for accurate performance and quality assessment is the use of both
rocess AND risk-adjusted outcome measures in this evaluation. Outcomes are
ssessed by hierarchic, multivariable logistic regression techniques believed to be
ost representative of accurate clinical risk assessment. In the National Quality
orum Cardiac Surgery Performance Measures, set structural measures were delib-
rately included as well, completing the Donabedian triad of quality measurement.
In this edition of the Journal, Nilsson and colleagues1 use a new application 
n old technique to assess risk in cardiac surgery. Artificial neural networks (ANNs)
ave variously been applied to large observational datasets in medicine, a number
f which have been in cardiac surgery. The results have mostly been variable
ompared with more conventional methods of risk adjustment, including Bayesian
odels, logistic regression models, and, more recently, hierarchic modeling, whichs thought to more accurately account for clustering of observations within provid-
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Lrs. Within the limitations of comparison of risk models
cross different datasets, Nilsson and colleagues’ analysis
oes not provide sufficient evidence to abandon these cur-
ent and more accepted risk-modeling techniques.
As pointed out by the authors, however, one prospective
heoretic advantage of the ANN approach is that, in analyz-
ng the large dataset necessary for model development, it
ould be possible to create a single model metric encom-
assing all adult cardiac surgery cases. This in turn could
ecome the benchmark for profiling an individual provider’s
erformance within his or her overall clinical practice,
ather than breaking the performance metrics down by pro-
edure (coronary artery bypass graft, valve, valve  coro-
ary artery bypass graft).
The limitations inherent in this analysis are informative
s well. First, models of all types perform optimally when
pplied to the datasets from which the model was devel-
ped; model performance (and therefore accuracy of risk
valuation) will vary somewhat when the ANN model is
pplied to the 1995 EuroSCORE dataset model, as was the
ase here. Second, the use of the 1995 EuroSCORE dataset
resents limitations in extrapolation of these findings to
urrent clinical practice; today’s practice of cardiac surgery
s more complex with higher-risk patients overall, and all
isk models perform least well at the extremes (low and
igh) of predicted risk. Thus, application of the ANN meth-
dology to a contemporary dataset, and in particular the
igh-risk end of that dataset, would need to be carefully
valuated and tested before use in clinical practice or pro-
ider evaluation. Third, most surgeons do not consider
reoperative patient risk to be equivalent across all adult
rocedure categories. Although a comprehensive model is
f interest, when it is being proposed as a predictive model,
dditional contemporary data on the predictive power
ithin procedure category groups will be needed before
ncorporation into clinical practice. Only if the ANN model
an in addition predict risk more accurately within the
rocedure subsets will there be renewed interest in this
odeling technique.
If this article does not describe a new, improved meth-
dology for risk assessment, why, then, is it important? Its
rincipal value lies in the fact that it illustrates and empha-
izes the continued “scientific investment” effort on the part
f cardiac surgery. At its most granular level, 3 points can
e made: (1) This article and editorial are discussing the
erits of new and different risk-adjustment modeling tech-
iques for cardiac surgery because the optimal risk model
or outcomes assessment does not exist; (2) this voluntary,
The Journal of Thorarovider-driven investigation into quality and performance
epresents an important contribution to moving this “scien-
ific investment” forward; and (3) the commitment to this
egree of “scientific investment” does not currently exist
lsewhere in medicine. At the 10,000 foot level, it is this
ame degree of “scientific investment” that has led to the
ontributions made within this specialty to Continuous
uality Improvement in medicine, which are equally un-
recedented compared with other remaining provider
roups.
The willingness to voluntarily embrace, from both a
eadership and financial perspective, this “scientific in-
estment” by the practice of cardiac surgery has been a
allmark of the international effort by the specialty. In
his year of 2006, cardiac surgery might finally see if
here is any real return on this investment, in both prac-
ice and politics.
In practice, it is clear that the information generated from
his “scientific investment” is not being communicated cor-
ectly, if at all, to the majority of patients presenting with
schemic heart disease before undergoing percutaneous cor-
nary interventions.E3 This is particularly important in p-
ients with 3-vessel disease, in whom the mortality and
orbidity from the procedures (coronary artery bypass
rafting vs percutaneous coronary intervention) are equiv-
lent, the long-term 3-year mortality outcomes favor coro-
ary artery bypass grafting by up to 43%,E4 and the long
erm financial and clinical effectiveness argument for
lective multivessel or left main percutaneous coronary
ntervention simply cannot be constructed.E5
In politics, it seems that defining decisions about the P4P
ill be made in 2006. Thus, it is of paramount importance
hat this “scientific investment” be represented as critical for
uccess at all levels of provider evaluation and for all types
f providers. The remarkable improvement in quality of
are delivered by cardiac surgeons during the past 15 years
s a direct result of this “scientific investment.” The return
n this investment has directly accrued to the patients who
ndergo cardiac surgery. If this “scientific investment” par-
digm is abandoned as P4P moves forward, patients who
ndergo cardiac surgery will irrevocably see their return
rom this investment disappear. In other areas of medicine,
his return has yet to be realized.
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